Differential expression of CD40 and CD95 in ovarian carcinoma

Purpose: The role of CD95 (Fas) as a mediator of apoptosis has been well documented. CD40 ligation has been recently shown to initiate apoptosis and modulate CD95 mediated apoptosis in normal and some neoplastic tissues. Here we report the expression of CD95 and CD40 in cryopreserved cell suspensions from ovarian cancer associated ascites, fresh primary and recurrent ovarian carcinoma (OVCA) specimens, and ten established ovarian cancer cell lines. The effect of CD95 and CD40 receptor binding on apoptosis is described in two cell lines.

Experimental design: Ascites specimens, fresh primary and recurrent OVCA specimens were dissociated to single cell suspensions. Expression of CD95 and CD40 was analyzed using flow cytometry. Apoptosis was determined via annexin uptake by flow cytometry following incubation with anti-CD95 antibody, CH11 and trimeric CD40L.

Results: Ascites showed the highest expression of both CD95 and CD40. Recurrent OVCA, in contrast, expressed low levels of CD95 and CD40. Primary OVCA showed moderate expression of both receptors. CD40 expression in ascites was significantly greater when compared to solid specimens (p < 0.05). Both CD40 and CD95 were strongly expressed in eight of ten cell lines studied. Binding of CD40L did not influence CD95 mediated apoptosis.

Conclusions: CD40 is ubiquitously expressed in ovarian carcinomas and expression differs between ascites and solid tumor. There may be differential expression of both CD40 and CD95 in recurrent vs primary ovarian carcinoma, which may contribute to increased clinical malignancy of recurrent disease. In contrast to other epithelial malignancies, CD40 ligation does not appear to modulate CD95 mediated apoptosis.

Apoptosis; Epithelial malignancy

[1] Piver M. S.: Handbook of Gynecologic Oncology 1996, Buffalo, NY (Suny Buffalo), Little, Brown Medical Division.

[2] Greenlee R. T., Murray T., Bolden S., Wingo P. A.: "Cancer statistics, 2000". CA Cancer J. Clin., 2000, 50, 7.

[3] Disaia P., Creasman W. T.: "Epithelial Ovarian Cancer". 2002, 289.

[4] Mackensen A., Lindemann A., Mertelsmann R.: "Immunostimulatory cytokines in somatic cells and gene therapy of cancer" Cytokine Growth Factor Rev., 1997, 8, 119.

[5] Trauth B. C., Klas C., Peters A. M., Matzku S., Moller P., Falk W et al.: "Monoclonal antibody-mediated tumor regression by in duetion of apoptosis". Science, 1989, 245, 301.

[6] Yitetta E. S., Uhr J. W.: "Monoclonal antibodies as agonists: an expanded role for their use in cancer therapy". Cancer Res., 1994, 54, 5301.

[7] Smith C. A.,F arrah T.,G oodwin R. G.: "The TNF receptor superfamily of cellular and viral proteins: activation, costimulation. and death". Cell., 1994, 76, 959.

[8] Krammer P. H.: "CD95(APO-l/Fas)-mediated apoptosis: live and let die". Adv. lmmunol., 1999. 71. 163.

[9] Bodmer J. L., Schneider P., Tschopp J.:'The molecular architecture of the TNF superfamily". Trends Biochem. Sci., 2002, 27, 19.

[10] CohenJ .J .,D uke R. C.,F adok V. A.,S ellins K. S.: "Apoptosis and programmed cell death in immunity''. Ann. Rev. Immunol., 1992, 10, 267.

[11] Suda T., Okazaki T., Naito Y., Yokota T., Arai N., Ozaki S. et al "Expression of the Fas ligand in cells of T cell lineage". J lmmunol.. 1995, 154, 3806.

[12] De Maria R., Testi R.: "Fas-FasL interactions: a common pathogenetic mechanism in organ- specific autoimmunity". lmmunol Today, 1998, 19, 121.

[13] Weintraub J.P., Godfrey Y., Wolthusen P.A., Cheek R. L., Eisenberg R. A., Cohen P. L.: "Immunological and pathological consequences of mutations in both Fas and Fas ligand". Cell lmmunol., 1998, 186, 8.

[14] Griffith T. S., Brunner T., Fletcher S. M., Green D. R., Ferguson T. A.: "Fas ligand-induced apoptosis as a mechanism of immune privilege" Science, 1995, 270, 1189.

[15] Foghi A., Teerds K. J., van der Donk H., Moore N. C., Dorrington J.: "Induction of apoptosis in thecal/interstitial cells: action of transforming growth factor (TGF) alpha plus TGF beta on bcl-2 and interleukin-l beta-converting enzyme". J. Endocrinol., 1998, 157, 489.

[16] Spencer S.J ., Cataldo N. A., Jaffe R. B.: "Apoptosis in the human female reproductive tract". Obstet.Gynecol. Surv., 1996, 51, 314.

[17] Ghahremani M., Foghi A., Dorrington J. H.: "Activation of Fas ligand/receptor system kills ovarian cancer cell lines by an apoptotic mechanism". Gynecol. Oneal., 1998, 70, 275.

[18] Garban H.J., Bonavida B.: "Nitric oxide sensitizes ovarian tumor cells to Fas-induced apoptosis". Gynecol. Oneal., 1999, 73, 257.

[19] Milner A. E., Palmer D. H.,H odgkin E. A., Eliopoulos A. G., Knox P. G., Poole C. J. et al.: "Induction of apoptosis by chemotherapeutic drugs: the role of FADD in activation of caspase-8 and synergy with death receptor ligands in ovarian carcinoma cells". Cell Death Dijjer., 2002, 9, 287.

[20] Wakahara Y., Nawa A., Okamoto T., Hayakwa A., Kikkawa F., Suganama N. et al.: "Combination effect of anti-Fas antibody and chemotherapeutic drugs in ovarian cancer cells in vitro". Onealogy, 1997, 54, 48.

[21] Nagata S.: "Fas and Fas ligand: a death factor and its receptor" Adv. lmmunol., 1994, 57, 129.

[22] Peter M. E., Krammer P.H.: "Mechanisms of CD95 (AP0-1/Fas)mediated apoptosis". Curr. Opin. lmmunol., 1998, 10. 545.

[23] Singer G. G., Carrera A. C., Marshak-Rothstein A., Martinez C., Abbas A. K.: "Apoptosis, Fas and systemic autoimmunity: the MRL-lpr/lpr model". Curr. Opin. Immunol., 1994, 6, 913.

[24] Grewal I. S., Flavell R. A.: "CD40 and CD154 in cell-mediated immunity". Ann. Rev. Immunol., 1998, /6, 111.

[25] Noelle R. J., Ledbetter J. A., Aruffo A.: "CD40 and ligand, an essential ligand-receptor pair for thymus-dependent B cell activation". lmmunol. Today, 1992, 13, 431.

[26] Schonbeck U., Libby P.: "The Cd40/CD 154 receptor/ligand dyad" Cell. Mo/. Life Sci., 2001, 58, 4.

[27] Clark E. A., Ledbetter J. A.: "Activation of human B cells mediated through two distinct cell surface differentiation antigens, Bp35 and BpSO". Proc. Natl. Acad.- Sci. USA, 1986, 83, 4494.

[28] Hellquist H. B., Olejnicka B., Jadner M., Andersson T., Sederholm C.: "Fas receptor is expressed in human lung squamous cell carcinomas, whereas bcl-2 and apoptosis are not pronounced: a preliminary report". Br. J. Cancer, 1997, 76, 175.

[29] Hellquist H. B.: "Apoptosis in epithelial hyperplastic laryngeal lesions". Acta Otolaryngol., 1997, (suppl.) 527, 25.

[30] Koomagi R.,V olm M.: "Expression of Fas (CD95/APO-l) and Fas ligand in lung cancer, its prognostic and predictive relevance". Int. J. Cancer, 1999, 84, 239.

[31] Koshiji M., Adachi Y., Sogo S.,T aketani S., Oyaizu N.,T han S. et al.: "Apoptosis of colorectal adenocarcinoma (COLO 201) by tumour necrosis factor-alpha (T NF-alpha) and/or interferongamma (IFN-gamma), resulting from down-modulation of Bcl-2 expression". Clin. Exp. Immunol., 1998, 111, 211.

[32] Lee S. H., Shin M. S., Park W. S., Kim S. Y., Dong S. M., Pi J. H. et al.: "Alterations of Fas (AP0-1/CD95) gene in transitional cell carcinomas of urinary bladder". Cancer Res., 1999, 59, 3068.

[33] Lee S. H., Lee J. Y., Park W. S., Kim S. Y., Jang J. J., Yoo N. J.: "Transitional cell carcinoma expresses high levels of Fas ligand in vivo". Brit. J. Urol., 1999, 83, 698.

[34] Houghton J. A., Harwood F. G., Gibson A. A., Tillman D. M.: "The fas signaling pathway is functional in colon carcinoma cells and induces apoptosis". Clin. Cancer Res., 1997, 3, 2205.

[35] Moller P., Koretz K., Leithauser F., Bruderlein S., Henne C., Quentmeier A., Krammer P. H.: "Expression of AP0-1 (CD95), a member of the NGF/TNF receptor superfamily, in normal and neoplastic colon epithelium". Int. J. Cancer, 1994, 57, 371.

[36] Lefthauser F., Dhein J., Mechtersheimer G., Koretz K., Bruderlein S., Henne C. et al.: "Constitutive and induced expression of APO-1, a new member of the nerve growth factor/tumor necrosis factor receptor superfamily, in normal and neoplastic cells". Lab Invest., 1993, 69, 415.

[37] Imai A.,H oribe S.,T akagi A.,O hno T.,T amaya T.: "Frequent expression of Fas in gonadotropin-releasing hormone receptor- bearing tumors". Eur. J. Obstet. Gynecol. Reprod. Biol., 1997, 74, 73.

[38] W hiteside T. L., Rabinowich H.: "The role of Fas/FasL in immunosuppression induced by human tumors". Cancer lmmunol. lmmunother., 1998, 46, 175.

[39] Ghamande S., Hylander B. L., Oflazoglu E., Shasikant L., Fanslow W., Repasky E. A.: "Recombinant CD40 ligand therapy has sinificant antitumor effects on CD40-positive ovarian tumor xenografts grwon in SCID mice and demonstrates an augmented effect with cisplatin". Cancer Res., 2001, 61, 7556.

[40] Gallagher N. J., Eliopoulos A. G., Agathangelo A., Oates J., Crocker J.,Y oung L. S.: "CD40 activation in epithelial ovarian carcinoma cells modulates growth, apoptosis, and cytokine secretion". J. Clin. Pathol. Mol. Pathol., 2002, 55, 110.

[41] Hirano A., Longo D. L., Taub D. D., Ferris D. K., Young L. S., Eliopoulos A. G. et al.: "Inhibition of human breast carcinoma growth by a soluble recombinant human CD40 ligand". Blood, 1999, 93, 2999.

[42] Eliopoulos A. G., Davies C., Knox P. G., Gallagher N. J., Afford S. C., Adams D. H., Young L. S.: "Cd40 induces apoptosis in carcinoma cells through activation of cytotoxic ligands of the tumor necrosis factor superfamily". Mol. Cell Biol., 2000, 20, 5503.

[43] Lagresle C.,M ondiere P., Bella C., Krammer P. H., Defrance T.: "Concurrent engagement of CD40 and the antigen receptor protects naive and memory human B cells from AP0-1/Fas-mediated apoptosis". J. Exp. Med., 1996, 183, 1377.

[44] Nakanishi K., Matsui K., Kashiwarnura S., Nishioka Y., Nomura J., Nishimura Y. et al.: "IL-4 and anti-CD40 protect against Fasmediated B cell apoptosis and induce B cell growth and differentiation". Int. Immunol., 1996, 8, 791.

[45] Garrone P., Neidhardt E. M., Garcia E., G汕bert L., van Kooten C., Banchereau J.: "Fas ligation induces apoptosis of CD40-activated human B lymphocytes". J. Exp. Med., 1995, 182, 1265.

[46] Chu P., Deforce D., Pedersen I. M., Kim Y., Kitada S., Reed J. C., Kipps T. J.: "Latent sensitivity to Fas-mediated apoptosis after CD40 ligation may explain activity of CD 154 gene therapy in chronic lymphocytic leukemia". Proc. Natl. Acad. Sci., 2002, 99, 3854.

[47] An S., Yap D., Knox K. A.: "Ligation of CD40 potentiates Fasmediated activation of the cysteine protease CPP32, cleavage of death substrate PARP, and apoptosis in Ramos-Burkitt lymphoma B cells". Cell lmmunol., 1997, 18, 139.

[48] Xerri L., Bouabdallah R., Devilard E., Hassoun J., Stoppa A. M., Birg F.: "Sensitivity to Fas-mediated apoptosis is null or weak in B-cell non-Hodgkin's lumphomas and is moderately increased by CD40 ligation". Br. J. Cancer, 1998, 78, 225.

[49] Cooke P. W., James N. D., Ganesan R., Wallace M., Burton A., Young L. S.: "CD40 expression in bladder cancer". J. Pathol., 1999, 188, 38.

[50] Jakobson E., Jonsson G., Bjorck P., Paulie S.: "Stimulation of CD40 in human bladder carcinoma cells inhibits anti- Fas/APO-I (CD95)-induced apoptosis". Int. J. Cancer, 1998, 77, 849.

[51] Rokhlin 0. W., Bishop G. A., Hostager B. S., Waldschmidt T. J., Sidorenko S. P., Pavloff N. et al.: "Fas-mediated apoptosis in human prostatic carcinoma cell lines". Cancer Res., 1997, 57, 1758.

[52] Sbih-Lammali F., Clausse B., Ardila-Osorio H., Guerry R., Talbot M., Havouis S. et al.: "Control of apoptosis in Epstein Barr viruspositive nasopharyngeal carcinoma cells: opposite effects of CD95 and CD40 stimulation". Cancer Res., 1999, 59, 924.

[53] Posner M. R., Cavacini L. A., Upton M. P., Tillman K. C., Gornstein E. R., Norris C. M. Jr.: "Surface membrane-expressed CD40 is present on tumor cells from squamous cell cancer of the head and neck in vitro and in vivo and regulates cell growth in tumor cell lines". Clin. Cancer Res., 1999, 5, 2261.

[54] Wingett D. G., Vestal R. E., Forcier K., Hadjokas N., Nielson C. P.: "CD40 is functionally expressed on human breast carcinomas: variable inducibility by cytokines and enhancement of Fas-mediated apoptosis". Breast Cancer Res. Treat., 1998, 50, 27.

[55] Resito N.: "Not so Fas: Re-evaluating the mechanisms of immune privilege and tumor escape". Nature Med., 2000, 6, 493.

[56] W hiteside T. L.: "Tumour-induced death by immune cells: its mechanisms and consequences". Seminars in Cancer Biology, 2002, 12, 43.

[57] Baldwin R. L., Tran H., Karlan B. Y.: "Primary ovarian cancer cultures are resistant to Fas-mediated apoptosis". Gynecol. Oncol., 1999, 74, 265.